The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S42-S47, November 2004

PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY

  • ANTHONY V. D'AMICO

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis St., L-2 Level, Boston, Massachusetts 02215 (telephone: 617-732-7936; FAX: 617-975-0912)
    • ,
  • JUDD MOUL

      Affiliations

    • Financial interest and/or other relationship with AstraZeneca, Sanofi and Theralogix
    • ,
  • PETER R. CARROLL

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals
    • ,
  • LEON SUN
    • ,
  • DEBORAH LUBECK
    • ,
  • MING-HUI CHEN

From the Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, Department of Surgery and Urology Service, Center for Prostate Disease Research, Uniformed Services University and Walter Reed Army Medical Center, Bethesda, Maryland, Department of Urology, University of California, San Francisco, California, and Department of Statistics, University of Connecticut, Storrs, Connecticut

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the Department of Defense Center for Prostate Disease Research funded by the United States Army Medical Research and Material Command, Fort Dietrick, Maryland and the Prostate Cancer Foundation, formally known as CaPCURE.The opinions and assertions herein are the private views of the authors and are not to be construed as reflecting the views of the United States Army or Department of Defense.

PII: S0022-5347(05)61307-9

doi:10.1097/01.ju.0000141845.99899.12

The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S42-S47, November 2004

Article Tools

* Image Usage & Resolution